FDA Approves Qiagen's Therascreen EGFR Test as CDx for AstraZeneca NSCLC Drug | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved Qiagen's therascreen EGRF test as a companion diagnostic test for AstraZeneca's Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small lung cancer. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.